vs
AMERICAN REALTY INVESTORS INC（ARL）与Protalix BioTherapeutics, Inc.（PLX）财务数据对比。点击上方公司名可切换其他公司
AMERICAN REALTY INVESTORS INC的季度营收约是Protalix BioTherapeutics, Inc.的1.4倍（$13.0M vs $9.1M），AMERICAN REALTY INVESTORS INC净利率更高（75.2% vs -60.3%，领先135.5%），AMERICAN REALTY INVESTORS INC同比增速更快（8.1% vs -49.9%），过去两年AMERICAN REALTY INVESTORS INC的营收复合增速更高（4.6% vs -6.7%）
原温加顿地产投资者是一家房地产投资信托公司，主要投资于美国南部的购物中心，且项目大多以杂货店作为主力店。该公司在2021年8月被金考地产收购。
Protalix BioTherapeutics是一家以色列制药企业，核心产品为植物源酶制剂他利苷酶阿尔法，该产品已获美国食品药品监督管理局批准，用于治疗戈谢病，专注于开发创新生物技术药物服务患者需求。
ARL vs PLX — 直观对比
营收规模更大
ARL
是对方的1.4倍
$9.1M
营收增速更快
ARL
高出58.0%
-49.9%
净利率更高
ARL
高出135.5%
-60.3%
两年增速更快
ARL
近两年复合增速
-6.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $13.0M | $9.1M |
| 净利润 | $9.8M | $-5.5M |
| 毛利率 | — | 49.4% |
| 营业利润率 | -23.3% | -51.1% |
| 净利率 | 75.2% | -60.3% |
| 营收同比 | 8.1% | -49.9% |
| 净利润同比 | 6175.8% | -184.8% |
| 每股收益（稀释后） | $0.60 | $-0.06 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ARLPLX
| Q4 25 | $13.0M | $9.1M | ||
| Q3 25 | $12.8M | $17.9M | ||
| Q2 25 | $12.2M | $15.7M | ||
| Q1 25 | $12.0M | $10.1M | ||
| Q4 24 | $12.0M | $18.2M | ||
| Q3 24 | $11.6M | $18.0M | ||
| Q2 24 | $11.8M | $13.5M | ||
| Q1 24 | $11.9M | — |
净利润ARLPLX
| Q4 25 | $9.8M | $-5.5M | ||
| Q3 25 | $129.0K | $2.4M | ||
| Q2 25 | $2.8M | $164.0K | ||
| Q1 25 | $3.0M | $-3.6M | ||
| Q4 24 | $-161.0K | $6.5M | ||
| Q3 24 | $-17.5M | $3.2M | ||
| Q2 24 | $1.2M | $-2.2M | ||
| Q1 24 | $1.8M | — |
毛利率ARLPLX
| Q4 25 | — | 49.4% | ||
| Q3 25 | — | 53.4% | ||
| Q2 25 | — | 62.5% | ||
| Q1 25 | — | 19.1% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 53.4% | ||
| Q2 24 | — | 29.8% | ||
| Q1 24 | — | — |
营业利润率ARLPLX
| Q4 25 | -23.3% | -51.1% | ||
| Q3 25 | -12.3% | 11.9% | ||
| Q2 25 | -8.3% | 7.5% | ||
| Q1 25 | -6.8% | -41.0% | ||
| Q4 24 | -14.8% | 39.6% | ||
| Q3 24 | -17.8% | 22.2% | ||
| Q2 24 | -10.8% | -18.0% | ||
| Q1 24 | -12.7% | — |
净利率ARLPLX
| Q4 25 | 75.2% | -60.3% | ||
| Q3 25 | 1.0% | 13.2% | ||
| Q2 25 | 23.2% | 1.0% | ||
| Q1 25 | 24.7% | -35.8% | ||
| Q4 24 | -1.3% | 35.6% | ||
| Q3 24 | -150.4% | 18.0% | ||
| Q2 24 | 9.9% | -16.4% | ||
| Q1 24 | 14.7% | — |
每股收益（稀释后）ARLPLX
| Q4 25 | $0.60 | $-0.06 | ||
| Q3 25 | $0.01 | $0.03 | ||
| Q2 25 | $0.18 | $0.00 | ||
| Q1 25 | $0.18 | $-0.05 | ||
| Q4 24 | $-0.01 | $0.10 | ||
| Q3 24 | $-1.08 | $0.03 | ||
| Q2 24 | $0.07 | $-0.03 | ||
| Q1 24 | $0.11 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $89.1M | $14.7M |
| 总债务越低越好 | $214.4M | — |
| 股东权益账面价值 | $617.4M | $48.2M |
| 总资产 | $1.1B | $82.3M |
| 负债/权益比越低杠杆越低 | 0.35× | — |
8季度趋势，按日历期对齐
现金及短期投资ARLPLX
| Q4 25 | $89.1M | $14.7M | ||
| Q3 25 | $82.8M | $13.6M | ||
| Q2 25 | $73.5M | $17.9M | ||
| Q1 25 | $88.7M | $19.5M | ||
| Q4 24 | $99.7M | $19.8M | ||
| Q3 24 | $131.6M | $27.4M | ||
| Q2 24 | $127.5M | $23.4M | ||
| Q1 24 | $130.9M | — |
总债务ARLPLX
| Q4 25 | $214.4M | — | ||
| Q3 25 | $227.0M | — | ||
| Q2 25 | $216.0M | — | ||
| Q1 25 | $201.7M | — | ||
| Q4 24 | $185.4M | — | ||
| Q3 24 | $183.8M | — | ||
| Q2 24 | $181.0M | — | ||
| Q1 24 | $181.8M | — |
股东权益ARLPLX
| Q4 25 | $617.4M | $48.2M | ||
| Q3 25 | $607.8M | $52.9M | ||
| Q2 25 | $607.8M | $49.9M | ||
| Q1 25 | $604.9M | $45.2M | ||
| Q4 24 | $601.8M | $43.2M | ||
| Q3 24 | $602.2M | $32.4M | ||
| Q2 24 | $619.9M | $28.6M | ||
| Q1 24 | $618.8M | — |
总资产ARLPLX
| Q4 25 | $1.1B | $82.3M | ||
| Q3 25 | $1.1B | $82.3M | ||
| Q2 25 | $1.1B | $78.5M | ||
| Q1 25 | $1.0B | $73.9M | ||
| Q4 24 | $1.0B | $73.4M | ||
| Q3 24 | $1.0B | $61.6M | ||
| Q2 24 | $1.0B | $91.5M | ||
| Q1 24 | $1.0B | — |
负债/权益比ARLPLX
| Q4 25 | 0.35× | — | ||
| Q3 25 | 0.37× | — | ||
| Q2 25 | 0.36× | — | ||
| Q1 25 | 0.33× | — | ||
| Q4 24 | 0.31× | — | ||
| Q3 24 | 0.31× | — | ||
| Q2 24 | 0.29× | — | ||
| Q1 24 | 0.29× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-5.6M | $2.0M |
| 自由现金流经营现金流 - 资本支出 | — | $1.6M |
| 自由现金流率自由现金流/营收 | — | 17.8% |
| 资本支出强度资本支出/营收 | — | 4.4% |
| 现金转化率经营现金流/净利润 | -0.57× | — |
| 过去12个月自由现金流最近4个季度 | — | $-13.6M |
8季度趋势，按日历期对齐
经营现金流ARLPLX
| Q4 25 | $-5.6M | $2.0M | ||
| Q3 25 | $8.0M | $-3.7M | ||
| Q2 25 | $-2.9M | $-5.2M | ||
| Q1 25 | $-7.4M | $-5.1M | ||
| Q4 24 | $1.1M | $4.0M | ||
| Q3 24 | $13.5M | $4.1M | ||
| Q2 24 | $-503.0K | $-3.6M | ||
| Q1 24 | $3.9M | — |
自由现金流ARLPLX
| Q4 25 | — | $1.6M | ||
| Q3 25 | — | $-4.2M | ||
| Q2 25 | — | $-5.7M | ||
| Q1 25 | — | $-5.4M | ||
| Q4 24 | — | $3.6M | ||
| Q3 24 | — | $4.0M | ||
| Q2 24 | — | $-3.8M | ||
| Q1 24 | — | — |
自由现金流率ARLPLX
| Q4 25 | — | 17.8% | ||
| Q3 25 | — | -23.7% | ||
| Q2 25 | — | -36.2% | ||
| Q1 25 | — | -53.0% | ||
| Q4 24 | — | 19.6% | ||
| Q3 24 | — | 22.4% | ||
| Q2 24 | — | -28.1% | ||
| Q1 24 | — | — |
资本支出强度ARLPLX
| Q4 25 | — | 4.4% | ||
| Q3 25 | — | 2.8% | ||
| Q2 25 | — | 2.8% | ||
| Q1 25 | — | 3.0% | ||
| Q4 24 | — | 2.3% | ||
| Q3 24 | — | 0.5% | ||
| Q2 24 | — | 1.3% | ||
| Q1 24 | — | — |
现金转化率ARLPLX
| Q4 25 | -0.57× | — | ||
| Q3 25 | 61.81× | -1.58× | ||
| Q2 25 | -1.03× | -31.91× | ||
| Q1 25 | -2.50× | — | ||
| Q4 24 | — | 0.61× | ||
| Q3 24 | — | 1.27× | ||
| Q2 24 | -0.43× | — | ||
| Q1 24 | 2.21× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ARL
暂无分部数据
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
